PMID- 36090983
OWN - NLM
STAT- MEDLINE
DCOM- 20220913
LR  - 20220915
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Immune responses in COVID-19 and tuberculosis coinfection: A scoping review.
PG  - 992743
LID - 10.3389/fimmu.2022.992743 [doi]
LID - 992743
AB  - BACKGROUND AND AIM: Patients with COVID-19 and tuberculosis coinfection are at an 
      increased risk of severe disease and death. We therefore sought to evaluate the 
      current evidence which assessed the immune response in COVID-19 and tuberculosis 
      coinfection. METHODS: We searched Pubmed/MEDLINE, EMBASE, Scopus, and Web of 
      Science to identify articles published between 2020 and 2021. We included 
      observational studies evaluating the immune response in patients with 
      tuberculosis and COVID-19 compared to patients with COVID-19 alone. RESULTS: Four 
      cross-sectional studies (372 participants) were identified. In patients with 
      asymptomatic COVID-19 and latent tuberculosis (LTBI), increased cytokines, 
      chemokines, growth factors and humoral responses were found. In addition, 
      patients with symptomatic COVID-19 and LTBI had higher leukocytes counts and less 
      inflammation. Regarding patients with COVID-19 and active tuberculosis (aTB), 
      they exhibited decreased total lymphocyte counts, CD4 T cells specific against 
      SARS-CoV-2 and responsiveness to SARS-CoV-2 antigens compared to patients with 
      only COVID-19. CONCLUSION: Although the evidence is limited, an apparent positive 
      immunomodulation is observed in patients with COVID-19 and LTBI. On the other 
      hand, patients with COVID-19 and aTB present a dysregulated immune response. 
      Longitudinal studies are needed to confirm these findings and expand knowledge.
CI  - Copyright (c) 2022 Flores-Lovon, Ortiz-Saavedra, Cueva-Chicana, Aperrigue-Lira, 
      Montes-Madariaga, Soriano-Moreno, Bell and Macedo.
FAU - Flores-Lovon, Kevin
AU  - Flores-Lovon K
AD  - Universidad Nacional de San Agustin de Arequipa, Arequipa, Peru.
AD  - Grupo de Investigacion en Inmunologia - GII, UNSA, Arequipa, Peru.
FAU - Ortiz-Saavedra, Brando
AU  - Ortiz-Saavedra B
AD  - Universidad Nacional de San Agustin de Arequipa, Arequipa, Peru.
AD  - Grupo de Investigacion en Inmunologia - GII, UNSA, Arequipa, Peru.
FAU - Cueva-Chicana, Luis A
AU  - Cueva-Chicana LA
AD  - Universidad Nacional de San Agustin de Arequipa, Arequipa, Peru.
AD  - Grupo de Investigacion en Inmunologia - GII, UNSA, Arequipa, Peru.
FAU - Aperrigue-Lira, Shalom
AU  - Aperrigue-Lira S
AD  - Universidad Nacional de San Agustin de Arequipa, Arequipa, Peru.
AD  - Grupo de Investigacion en Inmunologia - GII, UNSA, Arequipa, Peru.
FAU - Montes-Madariaga, Elizbet S
AU  - Montes-Madariaga ES
AD  - Universidad Nacional de San Agustin de Arequipa, Arequipa, Peru.
AD  - Grupo de Investigacion en Inmunologia - GII, UNSA, Arequipa, Peru.
FAU - Soriano-Moreno, David R
AU  - Soriano-Moreno DR
AD  - Unidad de Investigacion Clinica y Epidemiologica, Universidad Peruana Union, 
      Lima, Peru.
FAU - Bell, Brett
AU  - Bell B
AD  - Department of Radiation Oncology, Albert Einstein College of Medicine, Bronx, NY, 
      United States.
FAU - Macedo, Rodney
AU  - Macedo R
AD  - Grupo de Investigacion en Inmunologia - GII, UNSA, Arequipa, Peru.
AD  - Department of Radiation Oncology, Albert Einstein College of Medicine, Bronx, NY, 
      United States.
LA  - eng
GR  - R01 CA257509/CA/NCI NIH HHS/United States
PT  - Research Support, N.I.H., Extramural
PT  - Systematic Review
DEP - 20220826
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
SB  - IM
MH  - *COVID-19
MH  - *Coinfection
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Immunity
MH  - *Latent Tuberculosis
MH  - SARS-CoV-2
MH  - *Tuberculosis
PMC - PMC9459402
OTO - NOTNLM
OT  - COVID-19
OT  - Mycobacterium tuberculosis
OT  - SARS-CoV-2
OT  - coinfection
OT  - immunity
OT  - tuberculosis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/09/13 06:00
MHDA- 2022/09/14 06:00
PMCR- 2022/08/26
CRDT- 2022/09/12 03:53
PHST- 2022/07/13 00:00 [received]
PHST- 2022/08/08 00:00 [accepted]
PHST- 2022/09/12 03:53 [entrez]
PHST- 2022/09/13 06:00 [pubmed]
PHST- 2022/09/14 06:00 [medline]
PHST- 2022/08/26 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.992743 [doi]
PST - epublish
SO  - Front Immunol. 2022 Aug 26;13:992743. doi: 10.3389/fimmu.2022.992743. eCollection 
      2022.